News

We welcome our new owners

We would like to welcome our new international- as well as Scandinavian owners after closing this funding round.

New collaboration with Pharma

Oblique Therapeutics has entered into a collaboration agreement with a mid-sized Pharma for the development of the TRPV1 antibody.